What happens when you take methotrexate with nsaids?
Methotrexate is cleared primarily by the kidneys, both through glomerular filtration and through active secretion into the renal tubules by transporters in the OAT (organic anion transporter) family. About 80-90% of a dose is excreted unchanged in the urine. Anything that reduces renal blood flow or interferes with tubular secretion slows methotrexate elimination and raises blood levels.
NSAIDs (nonsteroidal anti-inflammatory drugs) work by inhibiting cyclooxygenase enzymes, which reduces prostaglandin synthesis. In the kidney, prostaglandins help maintain glomerular blood flow, especially when circulating volume is low or vasoconstrictor tone is high. By reducing prostaglandin production, NSAIDs cut renal blood flow, particularly in dehydrated or older patients. NSAIDs also compete directly with methotrexate at the renal tubular transporters, slowing its secretion into the urine.
The net result is delayed methotrexate clearance and higher exposure. In low-dose weekly methotrexate for rheumatoid arthritis (typically 7.5-25 mg/week) in patients with normal kidney function, the interaction is usually modest, and many rheumatologists allow careful NSAID use because both drugs are commonly needed for inflammatory arthritis. At higher methotrexate doses or in patients with kidney impairment, the interaction can be life-threatening.
Why is this important?
Methotrexate toxicity at elevated levels is severe. The bone marrow stops making blood cells (myelosuppression), causing neutropenia, thrombocytopenia, and anemia. Mucosal surfaces ulcerate, producing mouth sores, severe diarrhea, and gut bleeding. The liver may show transaminase rises or fulminant injury. Acute kidney injury can result from methotrexate precipitating in the renal tubules at very high concentrations. In the worst case, patients develop pancytopenia, sepsis, and death.
Published case series describe accidental methotrexate toxicity in older patients on regular ibuprofen, diclofenac, or naproxen, particularly when an intercurrent illness (viral gastroenteritis, urinary tract infection, dehydration) reduced their baseline kidney function. The methotrexate dose did not change, but its clearance dropped, levels rose, and toxicity emerged days to weeks later.
The risk profile is also affected by other concurrent medications. Combining methotrexate with NSAIDs, trimethoprim/sulfamethoxazole (Bactrim), proton pump inhibitors at high doses, and certain other renally-cleared or marrow-active drugs amplifies the danger. A recent pharmacovigilance database analysis confirmed that concomitant low-dose methotrexate and analgesic use produces a signal for hepatotoxicity, nephrotoxicity, and thrombocytopenia.
For cancer chemotherapy with high-dose methotrexate (1-12 g/m² infusions), NSAIDs are absolutely contraindicated around the infusion period. Even short delays in methotrexate clearance produce dramatic spikes in exposure and can lead to fatal toxicity despite leucovorin rescue.
What should you do?
If you take low-dose weekly methotrexate for an autoimmune condition, talk to your prescriber before starting any NSAID, including over-the-counter ibuprofen, naproxen, or aspirin at anti-inflammatory doses. Many rheumatologists are comfortable with occasional NSAID use in patients with normal kidney function, normal hydration, and stable methotrexate levels, but it should be a coordinated decision rather than a self-prescribed one.
Avoid NSAIDs if you have reduced kidney function (eGFR below 60 mL/min/1.73 m²), if you are dehydrated, if you are unwell with vomiting or diarrhea, or if you are over 65 with multiple comorbidities. In these situations, methotrexate clearance is already vulnerable, and adding NSAIDs significantly raises the risk of acute toxicity.
Around the time of high-dose methotrexate chemotherapy, stop all NSAIDs at least 24-48 hours before the infusion and avoid them until the methotrexate level has cleared (usually 72-96 hours, sometimes longer). Your oncology team will give you specific instructions.
For pain or fever in low-dose methotrexate patients, acetaminophen (paracetamol) up to 3 g daily is usually a safer alternative because it does not affect renal hemodynamics or compete with methotrexate at tubular transporters. Topical NSAIDs (diclofenac gel) have low systemic absorption and are generally safer than oral NSAIDs for localized musculoskeletal pain.
If you have already been taking the combination and are concerned, do not stop methotrexate on your own. Instead, call your prescriber. They may want to check a CBC, liver function, and creatinine, and review whether the NSAID is essential or can be replaced.
Which specific products are affected?
The interaction applies to all methotrexate formulations: oral tablets (Rheumatrex, Trexall, generics), oral solution (Xatmep), subcutaneous injection (Otrexup, Rasuvo, generic prefilled syringes), and IV/IM injection. Both low-dose weekly autoimmune dosing and high-dose chemotherapy dosing are affected, though the magnitude of risk is far greater with high doses.
On the NSAID side, the interaction is a class effect. It applies to ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn), diclofenac (Voltaren, Cambia), indomethacin, meloxicam (Mobic), celecoxib (Celebrex), ketorolac (Toradol), piroxicam (Feldene), and others. COX-2 selective agents like celecoxib are not safer in this context because they still affect renal prostaglandins. Aspirin at low cardioprotective doses (81 mg daily) is usually not clinically problematic, but anti-inflammatory aspirin doses (1-4 g daily) interact like other NSAIDs.
Topical NSAIDs (diclofenac gel, ketoprofen patches) have much lower systemic exposure and are generally considered safe with low-dose weekly methotrexate. Acetaminophen, gabapentin, duloxetine, and short courses of tramadol are commonly used as safer pain alternatives.
The bottom line
NSAIDs reduce methotrexate clearance by cutting renal blood flow and competing at tubular transporters. In low-dose autoimmune use with normal kidneys, occasional NSAID use can be acceptable but should be coordinated with the prescriber. Avoid NSAIDs entirely with high-dose methotrexate chemotherapy and in any patient with reduced kidney function, dehydration, or acute illness. Acetaminophen and topical NSAIDs are safer alternatives.